Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Terminated × Other solid neoplasm × Clear all

Phase

Phase 1 210 Phase 1/2 60 Phase 2 45 Phase NA 11 Phase EARLY_PHASE1 5 Phase 3 3 Phase 4 1 Phase 2/3 1

Status

Completed 5 Recruiting 3 Unknown 2 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 26 Thoracic 19 Breast 12 Other hematologic neoplasm 11 Genitourinary 11 Lymphoid 10 Gynecologic 7 Head & Neck 6 CNS 5 Sarcoma 4 Plasma cell 4 Myeloid 4 Dermatologic 4 Tumor-Agnostic 2 Other 2 Endocrine 2 Other solid neoplasm 1 NET 1 Classical hematology 1

Conditions

Interventions

nintedanib 1 Pemetrexed 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated

545 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡